How should GSK balance increasing the efficacy of its Shingrix vaccine against potential side effects?

Introduction

Balancing the efficacy of GSK's Shingrix vaccine against potential side effects is a critical trade-off that directly impacts public health outcomes and the company's market position. This scenario involves weighing the benefits of increased protection against shingles with the risks of adverse reactions. I'll analyze this trade-off through multiple lenses, considering scientific, business, and ethical perspectives.

Step 1

Clarifying Questions (3 minutes)

• Based on recent clinical data, I'm thinking efficacy improvements might be incremental. Could you share the current efficacy rate and the potential increase we're considering?

Why it matters: Helps quantify the potential benefit to weigh against risks. Expected answer: Current efficacy around 90%, looking at 2-5% increase. Impact on approach: Small increase might not justify significant side effect risks.

• Considering our market position, I assume Shingrix is a key revenue driver. What percentage of GSK's vaccine revenue does it represent?

Why it matters: Contextualizes the business impact of any changes. Expected answer: Significant portion, likely 30-40% of vaccine revenue. Impact on approach: Higher percentage would warrant more cautious approach to changes.

• Looking at user segments, I'm curious about the age distribution of Shingrix recipients. Can you provide a breakdown of key age groups?

Why it matters: Different age groups may have varying risk tolerances for side effects. Expected answer: Majority 50+, with significant 65+ population. Impact on approach: Older populations might be more sensitive to side effects, influencing our risk assessment.

• From a technical perspective, I'm wondering about the feasibility of targeted efficacy improvements. Is it possible to enhance efficacy for specific patient subgroups?

Why it matters: Could allow for a more nuanced approach to the trade-off. Expected answer: Some potential for targeted improvements, but challenging. Impact on approach: If feasible, could explore segmented strategies rather than one-size-fits-all.

• Considering regulatory timelines, what's the expected duration for approval of a modified vaccine formulation?

Why it matters: Affects the urgency and potential market impact of changes. Expected answer: 12-18 months for regulatory review and approval. Impact on approach: Longer timelines might favor more comprehensive testing and gradual improvements.